Literature DB >> 2334695

A spectroscopic study of the binding of N-7-substituted cap analogues to human protein synthesis initiation factor 4E.

S E Carberry1, E Darzynkiewicz, J Stepinski, S M Tahara, R E Rhoads, D J Goss.   

Abstract

The binding of N-7-substituted cap analogues to eIF-4E from human erythrocytes is described. Data presented here indicate that there is a correlation between the tightness of binding of these cap analogues to eIF-4E and their potency as inhibitors of protein synthesis. This result indicates that the inhibitory activity of the cap analogues is strictly a function of the affinity of the analogue for eIF-4E under equilibrium conditions. The pH dependence of binding of the cap analogues to eIF-4E indicates that the enolate form of the cap is preferred, as originally postulated by Rhoads et al. [(1983) Biochemistry 22, 6084-6088]. Data indicate that there are differences in the mode of binding of alkyl-substituted and aryl-substituted cap analogues to eIF-4E arising from favorable interactions of the phenyl ring with the guanosine moiety. These differences may explain the enhanced recognition of the aryl-substituted cap analogues by eIF-4E.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334695     DOI: 10.1021/bi00465a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

1.  Phosphorylation of eIF4E attenuates its interaction with mRNA 5' cap analogs by electrostatic repulsion: intein-mediated protein ligation strategy to obtain phosphorylated protein.

Authors:  Joanna Zuberek; Aleksandra Wyslouch-Cieszynska; Anna Niedzwiecka; Michal Dadlez; Janusz Stepinski; Wojciech Augustyniak; Anne-Claude Gingras; Zhibo Zhang; Stephen K Burley; Nahum Sonenberg; Ryszard Stolarski; Edward Darzynkiewicz
Journal:  RNA       Date:  2003-01       Impact factor: 4.942

2.  Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency.

Authors:  Ewa Grudzien; Janusz Stepinski; Marzena Jankowska-Anyszka; Ryszard Stolarski; Edward Darzynkiewicz; Robert E Rhoads
Journal:  RNA       Date:  2004-09       Impact factor: 4.942

Review 3.  Translation initiation of the HIV-1 mRNA.

Authors:  Théophile Ohlmann; Chloé Mengardi; Marcelo López-Lastra
Journal:  Translation (Austin)       Date:  2014-10-31

4.  Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG.

Authors:  J Stepinski; C Waddell; R Stolarski; E Darzynkiewicz; R E Rhoads
Journal:  RNA       Date:  2001-10       Impact factor: 4.942

5.  Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic translation initiation factor eIF-4E: increased cap affinity of the phosphorylated form.

Authors:  W B Minich; M L Balasta; D J Goss; R E Rhoads
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

Review 6.  Initiation of protein synthesis in eukaryotes.

Authors:  H O Voorma; A A Thomas; H A Van Heugten
Journal:  Mol Biol Rep       Date:  1994-05       Impact factor: 2.316

7.  The structure of eukaryotic translation initiation factor-4E from wheat reveals a novel disulfide bond.

Authors:  Arthur F Monzingo; Simrit Dhaliwal; Anirvan Dutt-Chaudhuri; Angeline Lyon; Jennifer H Sadow; David W Hoffman; Jon D Robertus; Karen S Browning
Journal:  Plant Physiol       Date:  2007-02-23       Impact factor: 8.340

8.  Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.

Authors:  Laurent Volpon; Michael J Osborne; Hiba Zahreddine; Andrea A Romeo; Katherine L B Borden
Journal:  Biochem Biophys Res Commun       Date:  2013-04-10       Impact factor: 3.575

Review 9.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

10.  Discrimination between mono- and trimethylated cap structures by two isoforms of Caenorhabditis elegans eIF4E.

Authors:  Hiroshi Miyoshi; Donard S Dwyer; Brett D Keiper; Marzena Jankowska-Anyszka; Edward Darzynkiewicz; Robert E Rhoads
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.